MAPK1 and non-small cell lung carcinoma: TCM components often exhibit less potent effects than modern drugs with clear targets, but the overall efficacy advantage of TCM preparations for tumor treatment is not only based on a simple additive effect of multiple “weak effects.” In vitro and in vivo EGFR mutant non-small-cell lung cancer models have shown that 20% of individual effective drug doses can completely block MAPK signaling when used in RAF+MEK+ERK or EGFR+RAF+MEK+ERK inhibitor combinations [42].